HCPLive Network

Immunogenicity Strongly Impacts Response to Adalimumab in Rheumatoid Arthritis

 
THURSDAY, Dec. 13 (HealthDay News) -- For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab antibodies, according to research published in the December issue of Arthritis & Rheumatism.

Charlotte L. Krieckaert, M.D., of the Jan van Breemen Research Institute in Amsterdam, and colleagues conducted a study involving 407 patients with RA who were naive to tumor necrosis factor antagonists and received either etanercept (203 patients) or adalimumab (204 patients).

The researchers found that, of the adalimumab group, 13, 15, and 16 percent, respectively, reached sustained low disease activity, sustained minimal disease activity, and sustained American College of Rheumatology/European League Against Rheumatism remission. The corresponding rates were 16, 11, and 12 percent in the etanercept group. The best outcomes were seen for adalimumab-treated patients without anti-adalimumab antibodies; the worst outcomes were seen for those with anti-adalimumab antibodies; and intermediate outcomes were seen for etanercept-treated patients. At least sustained minimal disease activity was seen for 40 percent of patients without anti-adalimumab antibodies; 23 percent of etanercept-treated patients; and 4 percent of patients with anti-adalimumab antibodies.

"Overall, etanercept and adalimumab treatment appear similar in inducing a good long-term clinical outcome," the authors write. "However, in the case of adalimumab this is strongly dependent on the presence or absence of anti-adalimumab antibodies."

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer (Wyeth) and Abbott Laboratories, both of which partially funded the study.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 
 

Further Reading
Xi E. Zheng, MD, PhD, shares her views on young-onset colorectal cancer at 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
In what could be New York City’s first case of Ebola, a doctor identified by the NY Post as Craig Spencer, 33, MD an emergency medicine physician at New York Hospital/Columbia-Presbyterian was rushed to a special Ebola unit at city-run Bellevue Hospital Center in Manhattan. Spencer returned 10 days ago from a stint as a volunteer with Doctors without Borders, caring for Ebola victims in Guinea, one of three West African nations with major outbreaks.
Patients diagnosed with diabetic retinopathy may be able to get a sense of how their condition has progressed without having to leave the comfort of their own home.
Monitoring devices among intensive care patients set off 2.5 million alarms in one month at a U.S. hospital, a new study of "alarm fatigue" reveals. The research was published online Oct. 22 in PLOS ONE.
While in-office visits may still be best, virtual analysis may be a valuable option in atopic dermatitis care, according to a new study published online Oct. 22 in JAMA Dermatology.
After weight-loss surgery, some patients may be at risk for developing severe headaches, a new study suggests. The report was published online Oct. 22 in Neurology.
The US health care system ranks last compared to other industrialized nations when it comes to affordability and patient access, according to a new survey published in the Oct. 23 issue of the New England Journal of Medicine.
More Reading